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SUMMARY
Surfactant deficiency and the resultant respiratory distress 
syndrome (RDS) seen in preterm infants is a major cause of 
respiratory morbidity in this population. Until recently, the 
contribution of surfactant to respiratory morbidity in infancy 
was limited to the neonatal period. It is now recognised that 
inborn errors of surfactant metabolism leading to surfactant 
dysfunction account for around 10% of childhood interstitial 
lung disease (chILD). These abnormalities can be detected by 
blood sampling for mutation analysis, thereby avoiding the 
need for lung biopsy in some children with chILD.
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INTRODUCTION
The role of surfactant deficiency in the development of RDS 
in preterm infants has long been appreciated and surfactant 
replacement is now a well established treatment modality. 
Term infants can also present with the clinical picture of 
RDS  as  a  result  of  surfactant  inactivation,  secondary  to 
conditions  such  as  meconium  aspiration  or  congenital 
pneumonia. However, it is less well known that inborn errors 
of surfactant metabolism leading to surfactant dysfunction are 
now thought to be an important cause of childhood interstitial 
lung disease. 
chILD
Childhood interstitial lung disease (chILD) is much rarer 
than interstitial lung disease (ILD) in adults and is typically 
associated  with  respiratory  distress,  diffuse  infiltrates  on 
chest imaging and abnormal lung histology. ChILD, like ILD 
in adults, comprises a spectrum of heterogeneous disorders. 
Until recently these have been poorly described, with the 
relevant literature consisting of case reports and small case 
series only. Previous attempts to classify chILD on the basis of 
the lung histology have used adult classifications, but it is now 
recognised that the histology and associated clinical outcome 
seen  in  children,  especially  those  under  2  years,  differs 
significantly from that of adults. Common histopathological 
findings of ILD in adults include desquamative interstitial 
pneumonia  (DIP),  lymphoid  interstitial  pneumonia  (LIP) 
and usual interstitial pneumonia (UIP). UIP has not been 
reported  in  any  paediatric  cases  to  date. Although  some 
overlap in histology does occur, for example with DIP, chILD 
is associated with a different aetiology compared to adults. 
This further emphasises that the adult classification of ILD is 
of little benefit in defining ILD in children. A recent review 
of 187 open lung biopsies in young children has identified 
pathology largely unique to children presenting in infancy, 
the majority presenting as either a term baby with features of 
RDS or with ‘chronic tachypnoea of infancy’. The underlying 
histology, clinical course and resultant prognosis have been 
described1 and are summarized in Table I.
The  overall  mortality  associated  with  chILD  is  21%2, 
but  almost  all  deaths  occur  in  those  with  developmental 
lung disorders and some of the surfactant deficiencies. In 
contrast,  infants  with  pulmonary  interstitial  glycogenosis 
(PIG) or neuroendocrine cell hyperplasia of infancy (NEHI) 
often  demonstrate  significant  clinical  improvement  over 
time. Although the presentation of these disorders is often 
similar, the age at presentation offers an important clue to 
the underlying diagnosis and subsequent prognosis. Children 
under two years with ILD present either in the neonatal period 
or in early infancy.
NEWBORN WITH chILD
This  is  commonly  a  term  infant  who  presents  shortly 
after  birth  with  severe  parenchymal  lung  disease  causing 
respiratory distress and oxygen requirement. Both the clinical 
presentation and the radiological features of diffuse ground 
glass opacities are similar to those more typically seen with 
prematurity and surfactant deficiency. Differential diagnoses 
such as pneumonia or meconium aspiration syndrome, leading 
to transient surfactant inactivation, must be excluded. Despite 
intensive  respiratory  support  with  mechanical  ventilation, 
inhaled nitric oxide or ECMO, this presentation is almost 
invariably fatal. The types of chILD associated with such 
an  early  and  aggressive  course  include  disorders  of  lung 
development  (alveolar  dysplasia  and  alveolar  capillary 
dysplasia) and two of the surfactant dysfunction disorders 
(surfactant protein B deficiency and ABCA3 gene mutations 
- although the latter may also have a less severe clinical 
course). PIG can also present perinatally but has a much more 
favourable outcome relative to the other causes, with very low 
reported mortality.  © The Ulster Medical Society, 2009.
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INFANT WITH chILD
This  group  of  children  with  ILD  present  with  ‘chronic 
tachypnoea of infancy’, usually in the first few months of 
life. Clinically this is characterised by persistent tachypnoea, 
hypoxia,  crackles  and  intercostal  recession.  The  ongoing 
oxygen requirement and increased work of breathing cause 
failure to thrive. Important differential diagnoses in these 
children are cystic fibrosis, aspiration and immunodeficiency 
with  recurrent  infection.  These  must  be  excluded  before 
chILD is considered. A number of conditions can give rise to 
chILD in infancy and include PIG, NEHI, surfactant protein 
C deficiency and less commonly ABCA3 gene mutations. 
The majority of the infants with these diagnoses experience 
clinical resolution over time.
The ability to define chILD using both the clinical picture and 
lung histology, is an extremely important development as it 
ensures that the most appropriate treatment and counselling 
are offered to children and their families. However, the recent 
development that surfactant dysfunction disorders underlie up 
to 10% of chILD may avoid the need for lung biopsy with its 




Pulmonary surfactant is a complex mixture of phospholipids 
and proteins, with surfactant proteins A, B and C constituting 
10% of surfactant. It is secreted by type II epithelial cells into 
the airways of the lung from 24 weeks gestation, although 
only in adequate amounts from 35 weeks gestation. Its main 
role is to reduce surface tension in the alveoli following the 
onset of breathing thereby facilitating lung expansion and 
preventing  alveolar  collapse  during  expiration.  Following 
birth, mechanical stretch of the lung further contributes to the 
secretion of lamellar bodies, the intracellular storage granules 
of  surfactant,  which  unravel  to  form  extended  tubes  and 
sheets characterised by the formation of tubular myelin. Both 
surfactant proteins A and B and surfactant lipids are necessary 
for the formation of tubular myelin. The surfactant forms a 
film at the alveoli-air interface, which is respread after each 
expiration to maintain a low surface tension and prevent lung 
collapse. The spreading and stability of the surfactant film 
requires SP-B and SP-C. Following secretion, both surfactant 
proteins and lipids are recycled by the respiratory epithelium. 
As well as reducing surface tension, surfactant also plays a 
role in the innate host defence of the lung. Surfactant protein 
Table I:
Classification of interstitial lung disease in children less than 2 years 
Disorders  Prevalence
Primary Disorders of Lung Development
(Aberration in primary molecular mechanism of lung and/or pulmonary vascular development)
5.8%
Lung Growth Abnormality
(Impaired pre or post natal alveolarisation, largely secondary)
24.6%
Pulmonary Interstitial Glycogenosis (PIG) 3.2%
Neuroendocrine cell hyperplasia of infancy (NEHI) 9.6%
Surfactant Dysfunction Disorders 9.6%
Miscellaneous
(e.g. systemic disease processes, immunocompromised states)
35.5%
Unable to classify 11.7%
Table II:
Surfactant metabolism dysfunction 1,2 and 3 genes.
Gene Type 1 (SFTP-B) Type 2 (SFTP- C) Type 3 (ABCA3)
MIM numbers 265120, 178640 610913, 178620 610921, 601615
Inheritance  Autosomal recessive Autosomal dominant, sporadic Autosomal recessive
Chromosome 2p12-11.2 8p21 16p13.3
Clinical 
features
Neonatal respiratory failure and 
death
Infantile and older chILD  with 
respiratory failure
Neonatal and early infantile 
respiratory failure. Some cases 
reported of older children with 
similar pattern to adult DIP
Lung histology Alveolar type II cell hyperplasia  
and alveolar proteinosis, 
interstitial inflammation and 
fibrosis
Variety of patterns including 
DIP, UIP, non-specific 
interstitial pneumonitis
Alveolar type II cell 
hyperplasia, accumulation of 
macrophages and proteinacious 
material in airspaces© The Ulster Medical Society, 2009.
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A and D primarily exert their effect in this area and are not 
necessary for the other functions of surfactant. ABCA3 is 
present in the membranes of the lamellar bodies in type II 
alveolar cells, where its main function is the transport of lipids 
important for surfactant.
It is now known that surfactant proteins B, C and ABCA3 are 
necessary for surfactant homeostasis and mutations in the 
genes encoding these proteins leads to surfactant dysfunction, 
giving rise to both lethal and chronic respiratory disease in 
infants (table II). 
Surfactant Protein B
Surfactant protein B deficiency is invariably fatal within the 
first few months of life. It is an autosomal recessive condition, 
most commonly due to a mutation at 121ins2. Gene frequency 
of this mutation is estimated to between 1 in 1000 to 1 in 
30003.  Infants  present  soon  after  birth  with  both  clinical 
and radiological features of respiratory distress syndrome, 
which has a rapidly progressive course. This is refractory 
to  standard  therapies  such  as  surfactant  replacement  and 
assisted ventilation, with the only effective treatment being 
a lung transplant.  Lung histology shows pulmonary alveolar 
proteinosis (PAP).
Surfactant Protein C
Surfactant  protein  C  is  encoded  by  the  SFTPC  gene  on 
chromosome  8.  Inherited  surfactant  protein  C  deficiency 
is a rare cause of both acute and chronic lung disease in 
both  infants,  children  and  into  adulthood.  Infants  usually 
present with interstitial lung disease that may be exacerbated 
by  respiratory  infections.  Histologically  the  condition  is 
characterised by chronic pneumonitis of infancy (CPI) or 
non-specific interstitial pneumonitis (NSIP)4. As with some 
other surfactant deficiencies, the only effective management is 
lung transplantation. Definitive diagnosis is made by genetic 
testing to identify the SFTPC gene.
Surfactant Protein ABCA3
ABCA3 is an ATP-binding transporter of lipids found in 
the membrane of lamellar bodies in type II alveolar cells. 
Initially mutations in this gene were thought to cause fatal 
lung disease in term neonates, but it is now recognised as a 
cause of chronic interstitial lung disease in older patients. One 
study looking at nine children with surfactant protein ABCA3 
mutations  found  that  the  range  of  presentation  in  these 
children varied from birth to four years5. Clinical features 
found included cough, crackles, clubbing and failure to thrive. 
Histopathological findings from lung biopsy were variable and 
included pulmonary alveolar proteinosis (PAP), desquamative 
interstitial  pneumonitis  (DIP)  and  non-specific  interstitial 
pneumonitis (NSIP). In one cohort of eight patients, three 
had  lung  transplantation  and  a  further  five  children  who 
did not require transplant had survived up to 18 years at the 
time of publication. Although some children clearly have 
a milder course, this mutation can cause severe respiratory 
insufficiency leading to death6.
CONCLUSIONS
chILD  represents  a  varied  group  of  disorders  which  are 
difficult to distinguish on clinical presentation and examination 
alone. The importance of obtaining an accurate diagnosis 
cannot be overstated as there is considerable disparity between 
the morbidity and mortality of these disorders. In the past, 
lung biopsy has been the only useful investigation and the 
diagnostic gold standard despite the potential complications 
associated with it. However, the identification of the genes 
responsible for surfactant dysfunction disorders avoids the 
need for a biopsy in approximately 10% of children. We 
therefore suggest that blood sampling for gene analysis be 
offered to all infants presenting with ‘chronic tachypnoea of 
infancy’ as the initial investigation and that lung biopsy is 
considered only if gene analysis is normal.
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